相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Assessment of Clinical Activity of PD-1 Checkpoint Inhibitor Combination Therapies Reported in Clinical Trials
Emmett V. Schmidt et al.
JAMA NETWORK OPEN (2020)
Collagen density regulates the activity of tumor-infiltrating T cells
Dorota E. Kuczek et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Transforming Growth Factor-β Signaling in Immunity and Cancer
Eduard Batlle et al.
IMMUNITY (2019)
Hyperprogression under Immunotherapy
Maxime Frelaut et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Characterization of tumor mutational burden (TMB), PD-L1, and DNA repair genes to assess correlation with immune checkpoint inhibitors (ICIs) response in metastatic renal cell carcinoma (mRCC).
Matthew Labriola et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Combined Inhibition of TGF- Signaling and the PD-L1 Immune Checkpoint Is Differentially Effective in Tumor Models
Heng Sheng Sow et al.
CELLS (2019)
Blockade of TGF-β signaling: a potential target for cancer immunotherapy?
Hendrik Ungefroren
EXPERT OPINION ON THERAPEUTIC TARGETS (2019)
Combinatorial Approaches With Checkpoint Inhibitors to Enhance Anti-tumor Immunity
Barbara Seliger
FRONTIERS IN IMMUNOLOGY (2019)
One checkpoint may hide another: inhibiting the TGFβ signaling pathway enhances immune checkpoint blockade
Aditi Gupta et al.
HEPATOBILIARY SURGERY AND NUTRITION (2019)
Cancer-associated fibroblasts: an emerging target of anti-cancer immunotherapy
Tongyan Liu et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2019)
The role of collagen in cancer: from bench to bedside
Shuaishuai Xu et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2019)
The Dark Side of Fibroblasts: Cancer-Associated Fibroblasts as Mediators of Immunosuppression in the Tumor Microenvironment
Lea Monteran et al.
FRONTIERS IN IMMUNOLOGY (2019)
Blocking TGF-β Signaling To Enhance The Efficacy Of Immune Checkpoint Inhibitor
Xianguang Bai et al.
ONCOTARGETS AND THERAPY (2019)
Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors
Satya Das et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Hyperprogressive Disease during Anti-PD-1 (PDCD1) / PD-L1 (CD274) Therapy: A Systematic Review and Meta-Analysis
Jong Yeob Kim et al.
CANCERS (2019)
TGF-β signaling in cell fate control and cancer
Yi Yu et al.
CURRENT OPINION IN CELL BIOLOGY (2019)
TGFβ Blockade Augments PD-1 Inhibition to Promote T-Cell-Mediated Regression of Pancreatic Cancer
Daniel R. Principe et al.
MOLECULAR CANCER THERAPEUTICS (2019)
Autocrine TGFβ Is a Survival Factor for Monocytes and Drives Immunosuppressive Lineage Commitment
Alba Gonzalez-Junca et al.
CANCER IMMUNOLOGY RESEARCH (2019)
Cold Tumors: A Therapeutic Challenge for Immunotherapy
Paola Bonaventura et al.
FRONTIERS IN IMMUNOLOGY (2019)
Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018
Lorenzo Galluzzi et al.
CELL DEATH AND DIFFERENTIATION (2018)
Cancer-Associated Fibroblasts Affect Intratumoral CD8+ and FoxP3+ T Cells Via IL6 in the Tumor Microenvironment
Takuya Kato et al.
CLINICAL CANCER RESEARCH (2018)
Immune Checkpoint Inhibitors and Cardiac Toxicity: An Emerging Issue
Gilda Varricchi et al.
CURRENT MEDICINAL CHEMISTRY (2018)
Tumor-Specific T-Cells Engineered to Overcome Tumor Immune Evasion Induce Clinical Responses in Patients With Relapsed Hodgkin Lymphoma
Catherine M. Bollard et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Canonical TGF-β Signaling Pathway Represses Human NK Cell Metabolism
Vanessa Zaiatz-Bittencourt et al.
JOURNAL OF IMMUNOLOGY (2018)
TGFβ drives immune evasion in genetically reconstituted colon cancer metastasis
Daniele V. F. Tauriello et al.
NATURE (2018)
Cancer immunotherapy using checkpoint blockade
Antoni Ribas et al.
SCIENCE (2018)
Enhanced preclinical antitumor activity of M7824, a bifunctional fusion protein simultaneously targeting PD-L1 and TGF-β
Yan Lan et al.
SCIENCE TRANSLATIONAL MEDICINE (2018)
Defining the role of the tumor vasculature in antitumor immunity and immunotherapy
Marco B. Schaaf et al.
CELL DEATH & DISEASE (2018)
Cancer-associated fibroblasts induce antigen-specific deletion of CD8+ T Cells to protect tumour cells
Matthew A. Lakins et al.
NATURE COMMUNICATIONS (2018)
Bifunctional immune checkpoint-targeted antibody-ligand traps that simultaneously disable TGF beta enhance the efficacy of cancer immunotherapy
Rajani Ravi et al.
NATURE COMMUNICATIONS (2018)
Inhibition of IL-10 and TGF- receptors on dendritic cells enhances activation of effector T-cells to kill cholangiocarcinoma cells
Chutamas Thepmalee et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2018)
Alteration of the Antitumor immune Response by Cancer-Associated Fibroblasts
Linda Ziani et al.
FRONTIERS IN IMMUNOLOGY (2018)
TGF-β in T Cell Biology: Implications for Cancer Immunotherapy
Amina Dahmani et al.
CANCERS (2018)
TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells
Sanjeev Mariathasan et al.
NATURE (2018)
Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors A Systematic Review and Meta-analysis
Daniel Y. Wang et al.
JAMA ONCOLOGY (2018)
Hyperprogressive Disease in Patients With Advanced Non-Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy
Roberto Ferrara et al.
JAMA ONCOLOGY (2018)
Epithelial-Mesenchymal Transition and Metastasis under the Control of Transforming Growth Factor
Yutaro Tsubakihara et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)
TGF-β-associated extracellular matrix genes link cancer-associated fibroblasts to immune evasion and immunotherapy failure
Ankur Chakravarthy et al.
NATURE COMMUNICATIONS (2018)
Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1
Stephane Champiat et al.
CLINICAL CANCER RESEARCH (2017)
The role of TGF-beta signaling in dendritic cell tolerance
Grace E. Esebanmen et al.
IMMUNOLOGIC RESEARCH (2017)
Regulation of the Immune Response by TGF-β: From Conception to Autoimmunity and Infection
Shomyseh Sanjabi et al.
COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY (2017)
Transforming growth factor-: A therapeutic target for cancer
Sulsal Haque et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2017)
Current Diagnosis and Management of Immune Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitor Therapy
Vivek Kumar et al.
FRONTIERS IN PHARMACOLOGY (2017)
A novel bifunctional anti-PD-L1/TGF-β Trap fusion protein (M7824) efficiently reverts mesenchymalization of human lung cancer cells
Justin M. David et al.
ONCOIMMUNOLOGY (2017)
Cardiotoxicity of immune checkpoint inhibitors
Gilda Varricchi et al.
ESMO OPEN (2017)
Hyperprogressors after Immunotherapy: Analysis of Genomic Alterations Associated with Accelerated Growth Rate
Shumei Kato et al.
CLINICAL CANCER RESEARCH (2017)
Cancer-associated fibroblasts modulate growth factor signaling and extracellular matrix remodeling to regulate tumor metastasis
Begum Erdogan et al.
BIOCHEMICAL SOCIETY TRANSACTIONS (2017)
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
Padmanee Sharma et al.
CELL (2017)
Immunogenic cell death in cancer and infectious disease
Lorenzo Galluzzi et al.
NATURE REVIEWS IMMUNOLOGY (2017)
Dichotomous roles of TGF-β in human cancer
Jennifer J. Huang et al.
BIOCHEMICAL SOCIETY TRANSACTIONS (2016)
Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma
Willy Hugo et al.
CELL (2016)
The urgent need to recover MHC class I in cancers for effective immunotherapy
Federico Garrido et al.
CURRENT OPINION IN IMMUNOLOGY (2016)
A phase 2 study of galunisertib, a novel transforming growth factor-beta (TGF-β) receptor I kinase inhibitor in patients with advanced hepatocellular carcinoma (HCC) and low serum alpha fetoprotein (AFP)
Sandrine J. Faivre et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies
J. Naidoo et al.
ANNALS OF ONCOLOGY (2015)
Role of TGFβ in regulation of the tumor microenvironment and drug delivery
Panagiotis Papageorgis et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2015)
Costs of cardiovascular disease prevention care and scenarios for cost saving: a micro-costing study from rural Nigeria
Marleen E. Hendriks et al.
JOURNAL OF HYPERTENSION (2015)
The consensus molecular subtypes of colorectal cancer
Justin Guinney et al.
NATURE MEDICINE (2015)
Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma
Michael A. Postow et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Immunological mechanisms of the antitumor effects of supplemental oxygenation
Stephen M. Hatfield et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
An approach for determining and measuring network hierarchy applied to comparing the phosphorylome and the regulome
Chao Cheng et al.
GENOME BIOLOGY (2015)
Remodeling components of the tumor microenvironment to enhance cancer therapy
Vasiliki Gkretsi et al.
FRONTIERS IN ONCOLOGY (2015)
First-in-Human Dose Study of the Novel Transforming Growth Factor-β Receptor I Kinase Inhibitor LY2157299 Monohydrate in Patients with Advanced Cancer and Glioma
Jordi Rodon et al.
CLINICAL CANCER RESEARCH (2015)
Indoleamine 2,3-dioxygenase pathways of pathogenic inflammation and immune escape in cancer
George C. Prendergast et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2014)
Systemic oxygenation weakens the hypoxia and hypoxia inducible factor 1α-dependent and extracellular adenosine-mediated tumor protection
Stephen M. Hatfield et al.
JOURNAL OF MOLECULAR MEDICINE-JMM (2014)
Phase I Study of GC1008 (Fresolimumab): A Human Anti-Transforming Growth Factor-Beta (TGFβ) Monoclonal Antibody in Patients with Advanced Malignant Melanoma or Renal Cell Carcinoma
John C. Morris et al.
PLOS ONE (2014)
Transforming Growth Factor-Beta and Matrix Metalloproteinases: Functional Interactions in Tumor Stroma-Infiltrating Myeloid Cells
Jelena Krstic et al.
SCIENTIFIC WORLD JOURNAL (2014)
Perspectives of TGF-beta inhibition in pancreatic and hepatocellular carcinomas
Cindy Neuzillet et al.
ONCOTARGET (2014)
Advanced Heat Map and Clustering Analysis Using Heatmap3
Shilin Zhao et al.
BIOMED RESEARCH INTERNATIONAL (2014)
Pirfenidone Inhibits Pancreatic Cancer Desmoplasia by Regulating Stellate Cells
Shingo Kozono et al.
CANCER RESEARCH (2013)
Tumor Stromal Architecture Can Define the Intrinsic Tumor Response to VEGF-Targeted Therapy
Neil R. Smith et al.
CLINICAL CANCER RESEARCH (2013)
Targeting TGF-β signaling in cancer
Lior H. Katz et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2013)
Oncology Meets Immunology: The Cancer-Immunity Cycle
Daniel S. Chen et al.
IMMUNITY (2013)
Type III TGF-β receptor downregulation generates an immunotolerant tumor microenvironment
Brent A. Hanks et al.
JOURNAL OF CLINICAL INVESTIGATION (2013)
TGF-β: Guardian of T Cell Function
Soyoung A. Oh et al.
JOURNAL OF IMMUNOLOGY (2013)
Nivolumab plus Ipilimumab in Advanced Melanoma
Jedd D. Wolchok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Cancer Stem Cells: Impact, Heterogeneity, and Uncertainty
Jeffrey A. Magee et al.
CANCER CELL (2012)
Phase I trial of gemcitabine and candesartan combination therapy in normotensive patients with advanced pancreatic cancer: GECA1
Yousuke Nakai et al.
CANCER SCIENCE (2012)
Molecular Pathways: Targeting the TGF-β Pathway for Cancer Therapy
Anna L. Smith et al.
CLINICAL CANCER RESEARCH (2012)
Regulation of EMT by TGFβ in cancer
Carl-Henrik Heldin et al.
FEBS LETTERS (2012)
TGFβ signalling in context
Joan Massague
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2012)
TGF-β blockade improves the distribution and efficacy of therapeutics in breast carcinoma by normalizing the tumor stroma
Jieqiong Liu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
TGF-β: the sword, the wand, and the shield of FOXP3+ regulatory T cells
Dat Q. Tran
JOURNAL OF MOLECULAR CELL BIOLOGY (2012)
Within tumors, interactions between T cells and tumor cells are impeded by the extracellular matrix
Helene Salmon et al.
ONCOIMMUNOLOGY (2012)
Tgf-β1 produced by activated CD4+ T Cells Antagonizes T Cell Surveillance of Tumor Development
Moses K. Donkor et al.
ONCOIMMUNOLOGY (2012)
Tumor Evasion from T Cell Surveillance
Katrin Toepfer et al.
JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY (2011)
Nonredundant Roles of IL-10 and TGF-β in Suppression of Immune Responses to Hepatic AAV-Factor IX Gene Transfer
Brad E. Hoffman et al.
MOLECULAR THERAPY (2011)
Indoleamine 2,3-dioxygenase is a signaling protein in long-term tolerance by dendritic cells
Maria T. Pallotta et al.
NATURE IMMUNOLOGY (2011)
Delivery of Molecular and Nanoscale Medicine to Tumors: Transport Barriers and Strategies
Vikash P. Chauhan et al.
ANNUAL REVIEW OF CHEMICAL AND BIOMOLECULAR ENGINEERING, VOL 2 (2011)
Targeting the transforming growth factor-beta signaling pathway in human cancer
Nagathihalli S. Nagaraj et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2010)
EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer
A. Singh et al.
ONCOGENE (2010)
Cancer-Expanded Myeloid-Derived Suppressor Cells Induce Anergy of NK Cells through Membrane-Bound TGF-beta 1
Hequan Li et al.
JOURNAL OF IMMUNOLOGY (2009)
Human Dendritic Cells Produce TGF-β1 under the Influence of Lung Carcinoma Cells and Prime the Differentiation of CD4+CD25+Foxp3+ Regulatory T Cells
Ingrid E. Dumitriu et al.
JOURNAL OF IMMUNOLOGY (2009)
Activin Signaling in Microsatellite Stable Colon Cancers Is Disrupted by a Combination of Genetic and Epigenetic Mechanisms
Barbara Jung et al.
PLOS ONE (2009)
Immunogenic and tolerogenic cell death
Douglas R. Green et al.
NATURE REVIEWS IMMUNOLOGY (2009)
Cutting edge:: Autocrine TGF-β sustains default tolerogenesis by IDO-competent dendritic cells
Maria L. Belladonna et al.
JOURNAL OF IMMUNOLOGY (2008)
Extracellular control of TGFβ signalling in vascular development and disease
Peter ten Dijke et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2007)
A unique subset of CD4+CD25high Foxp3+ T cells secreting interleukin-10 and transforming growth factor-β1 mediates suppression in the tumor microenvironment
Laura Strauss et al.
CLINICAL CANCER RESEARCH (2007)
Tolerogenic dendritic cells and the quest for transplant tolerance
Adrian E. Morelli et al.
NATURE REVIEWS IMMUNOLOGY (2007)
Interaction between phosphatidylserine and the phosphatidylserine receptor inhibits immune responses in vivo
PR Hoffmann et al.
JOURNAL OF IMMUNOLOGY (2005)
Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-β induction of transcription factor Foxp3
WJ Chen et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2003)
Reversal of tumor-induced immunosuppression by TGF-β inhibitors
S Wojtowicz-Praga
INVESTIGATIONAL NEW DRUGS (2003)
Reconstitution of lethally irradiated adult mice with dominant negative TGF-β type II receptor-transduced bone marrow leads to myeloid expansion and inflammatory disease
AH Shah et al.
JOURNAL OF IMMUNOLOGY (2002)
Mechanisms of TGF-beta-mediated apoptosis
N Schuster et al.
CELL AND TISSUE RESEARCH (2002)
The N domain of Smad7 is essential for specific inhibition of transforming growth factor-β signaling
A Hanyu et al.
JOURNAL OF CELL BIOLOGY (2001)
Immune-mediated eradication of tumors through the blockade of transforming growth factor-β signaling in T cells
L Gorelik et al.
NATURE MEDICINE (2001)
Oncogenic Ras represses transforming growth factor-β/Smad signaling by degrading tumor suppressor Smad4
D Saha et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
TGF-β released by apoptotic T cells contributes to an immunosuppressive milieu
WJ Chen et al.
IMMUNITY (2001)
分享论文
